Immuneering (IMRX) Depreciation & Amortization (CF) (2020 - 2026)
Immuneering (IMRX) posted quarterly Depreciation & Amortization (CF) of $81402.0 for Q1 2026, down 4.53% year-over-year from $85261.0 in Q1 2025, and up 7.26% quarter-over-quarter from $75889.0 in Q4 2025.
Immuneering (IMRX) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Immuneering's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $81402.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 4.53% year-over-year to $81402.0; the TTM figure through Mar 2026 stood at $320659.0 (down 8.61% YoY), while the FY2025 annual figure was $324517.0, down 8.79% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $81402.0, up from $75889.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $90533.0 in Q2 2024, with the low at $47704.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $78841.0 (2025), against an average of $78337.9.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) jumped 468.33% in 2022, then fell 11.88% in 2025.
- Immuneering's Depreciation & Amortization (CF) stood at $76862.0 in 2022, then advanced by 16.77% to $89754.0 in 2023, then retreated by 4.05% to $86116.0 in 2024, then dropped by 11.88% to $75889.0 in 2025, then gained by 7.26% to $81402.0 in 2026.
- Business Quant data shows IMRX's Depreciation & Amortization (CF) at $81402.0 in Q1 2026, $75889.0 in Q4 2025, and $78841.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 84,454.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 84,454.00 |
| Jun 30, 2026 | 84,454.00 |
| Mar 31, 2026 | 81,402.00 |
| Mar 31, 2026 | 81,402.00 |
| Dec 31, 2025 | 75,889.00 |
| Dec 31, 2025 | 75,889.00 |
| Sep 30, 2025 | 78,841.00 |
| Sep 30, 2025 | 78,841.00 |
| Jun 30, 2025 | 84,527.00 |
| Jun 30, 2025 | 84,527.00 |
| Mar 31, 2025 | 85,261.00 |
| Mar 31, 2025 | 85,261.00 |
| Dec 31, 2024 | 86,116.00 |
| Dec 31, 2024 | 86,116.00 |
| Sep 30, 2024 | 88,949.00 |
| Sep 30, 2024 | 88,949.00 |
| Jun 30, 2024 | 90,533.00 |
| Jun 30, 2024 | 90,533.00 |
| Mar 31, 2024 | 90,209.00 |
| Mar 31, 2024 | 90,209.00 |